Morgan Stanley·2026-09-11SectorBiopharma: GLP-1's-Takeaways from Physician Survey and Credit Card Spend Data
Goldman Sachs·2026-07-10SectorGlobal Healthcare: The Cardiology Renaissance: Monitoring Phase 3 ZEUS to assess cardiovascular outcomes with NLRP3 inhibition
Bernstein·2026-07-06SectorUS Biopharmaceuticals: GLP-1 Tracker: Keeping an eye out on NBRx as DTC ads and Medicare start to switch on (W E June 26th)
Goldman Sachs·2026-07-06SectorGlobal Healthcare: Pharmaceuticals: The Obesity Evolution: Medicare Volume Unlock — KOL Survey to Anticipate Early Impact